DE102021114711B4 - Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer - Google Patents

Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer Download PDF

Info

Publication number
DE102021114711B4
DE102021114711B4 DE102021114711.5A DE102021114711A DE102021114711B4 DE 102021114711 B4 DE102021114711 B4 DE 102021114711B4 DE 102021114711 A DE102021114711 A DE 102021114711A DE 102021114711 B4 DE102021114711 B4 DE 102021114711B4
Authority
DE
Germany
Prior art keywords
acid
amino
marking
precursors
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE102021114711.5A
Other languages
German (de)
English (en)
Other versions
DE102021114711A1 (de
Inventor
Frank Rösch
Martin Marcel
Tilmann Grus
Euy Sung Moon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medianezia De GmbH
Original Assignee
Medianezia GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102021114711.5A priority Critical patent/DE102021114711B4/de
Application filed by Medianezia GmbH filed Critical Medianezia GmbH
Priority to US18/567,891 priority patent/US20250235566A1/en
Priority to AU2022288744A priority patent/AU2022288744A1/en
Priority to PCT/EP2022/065440 priority patent/WO2022258637A1/de
Priority to EP22734235.9A priority patent/EP4351663A1/de
Priority to CN202280040063.2A priority patent/CN117642190A/zh
Priority to BR112023023149A priority patent/BR112023023149A2/pt
Priority to KR1020247000764A priority patent/KR20240019301A/ko
Priority to JP2023576067A priority patent/JP2024522200A/ja
Priority to CA3222226A priority patent/CA3222226A1/en
Publication of DE102021114711A1 publication Critical patent/DE102021114711A1/de
Application granted granted Critical
Publication of DE102021114711B4 publication Critical patent/DE102021114711B4/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paints Or Removers (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
  • Medicinal Preparation (AREA)
DE102021114711.5A 2021-06-08 2021-06-08 Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer Active DE102021114711B4 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE102021114711.5A DE102021114711B4 (de) 2021-06-08 2021-06-08 Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
JP2023576067A JP2024522200A (ja) 2021-06-08 2022-06-07 トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー
PCT/EP2022/065440 WO2022258637A1 (de) 2021-06-08 2022-06-07 Trislinker-konjugierte dimere markierungsvorläufer und daraus abgeleitete radiotracer
EP22734235.9A EP4351663A1 (de) 2021-06-08 2022-06-07 Trislinker-konjugierte dimere markierungsvorläufer und daraus abgeleitete radiotracer
CN202280040063.2A CN117642190A (zh) 2021-06-08 2022-06-07 缀合有三接头的二聚体标记前体和由其衍生的放射性示踪剂
BR112023023149A BR112023023149A2 (pt) 2021-06-08 2022-06-07 Precursores de marcação diméricos conjugados via um trislinker e radiotraçadores derivados dos mesmos
US18/567,891 US20250235566A1 (en) 2021-06-08 2022-06-07 Trislinker-conjugated dimeric labeling precursors and radiotracers derived therefrom
AU2022288744A AU2022288744A1 (en) 2021-06-08 2022-06-07 Trislinker-conjugated dimeric labelling precursors and radiotracers derived therefrom
CA3222226A CA3222226A1 (en) 2021-06-08 2022-06-07 Trislinker-conjugated dimeric labeling precursors and radiotracers derived therefrom
KR1020247000764A KR20240019301A (ko) 2021-06-08 2022-06-07 트리스링커-접합된 이량체 표지 전구체 및 이로부터 유도되는 방사성 추적자

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102021114711.5A DE102021114711B4 (de) 2021-06-08 2021-06-08 Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer

Publications (2)

Publication Number Publication Date
DE102021114711A1 DE102021114711A1 (de) 2022-12-08
DE102021114711B4 true DE102021114711B4 (de) 2023-11-02

Family

ID=82258261

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102021114711.5A Active DE102021114711B4 (de) 2021-06-08 2021-06-08 Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer

Country Status (10)

Country Link
US (1) US20250235566A1 (https=)
EP (1) EP4351663A1 (https=)
JP (1) JP2024522200A (https=)
KR (1) KR20240019301A (https=)
CN (1) CN117642190A (https=)
AU (1) AU2022288744A1 (https=)
BR (1) BR112023023149A2 (https=)
CA (1) CA3222226A1 (https=)
DE (1) DE102021114711B4 (https=)
WO (1) WO2022258637A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3248367A1 (en) * 2022-01-14 2023-07-20 Provincial Health Services Authority Radiolabeled compounds for imaging fibroblast-activating protein (FAP) and treating FAP-related disorders
WO2023222558A1 (en) 2022-05-14 2023-11-23 Zounek Alexis Nikolai Precursor and theranostic radiotracer with improved tumor retention
DE102022116009A1 (de) * 2022-06-28 2023-12-28 Positron Precision GmbH Fibroblasten-Aktivierungsprotein adressierender Präkursor und Radiotracer
CN115947775B (zh) * 2023-03-13 2023-06-09 北京先通国际医药科技股份有限公司 一种制备化合物（i）的方法和化合物（i）及其用途
CN117304125A (zh) * 2023-09-12 2023-12-29 北京师范大学 靶向PSMA的EuK二聚体化合物及其药用盐和应用
WO2025063849A2 (en) * 2023-09-21 2025-03-27 Erasmus University Medical Center Rotterdam Dimeric fap targeting agents
WO2025087229A1 (zh) * 2023-10-27 2025-05-01 四川科伦博泰生物医药股份有限公司 一类喹啉结构的配体化合物及其放射性或非放射性标记物以及应用
WO2025125335A1 (en) 2023-12-13 2025-06-19 Radiovaxx Gmbh Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group
CN120136958A (zh) * 2023-12-13 2025-06-13 无锡诺宇医药科技有限公司 Fap靶向放射性药物
WO2025125621A1 (en) 2023-12-14 2025-06-19 Radiovaxx Gmbh Cancer-associated protein-targeted strong or covalently binding precursor compounds and radiotracers
WO2025146433A1 (en) 2024-01-05 2025-07-10 Radiovaxx Gmbh Precursor and theranostic radiotracer with prolonged tumor retention
TW202535358A (zh) * 2024-01-11 2025-09-16 大陸商上海復星醫藥產業發展有限公司 一種ｆａｐ結合化合物、金屬錯合物及其用途
CN118271393B (zh) * 2024-05-31 2024-09-03 中国药科大学 一种靶向fap的二聚化合物及其探针和应用
EP4696686A1 (en) * 2024-08-15 2026-02-18 Tetrakit Technologies ApS Fapi theranostic compounds assembled with tetrazine ligation
CN119060093B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN119060094B (zh) * 2024-08-26 2025-09-05 广州医科大学附属第一医院（广州呼吸中心） 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用
CN118955353A (zh) * 2024-10-14 2024-11-15 南京恒远科技开发有限公司 一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法
CN119679977B (zh) * 2024-12-16 2025-09-05 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种Al18F示踪剂一体化冻干粉的制备方法、试剂盒及其应用
CN119409613B (zh) * 2025-01-03 2025-04-11 南京恒远科技开发有限公司 (s)-[2-(2-氰基-4,4-二氟吡咯烷-1-基)-2-氧代-乙基]氨基甲酸叔丁酯的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015055318A1 (en) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
US11167048B2 (en) * 2018-12-14 2021-11-09 The Curators Of The University Of Missouri Dual targeting ligand for cancer diagnosis and treatment
CN114502528B (zh) * 2019-09-20 2024-09-06 墨尔本大学 成像和治疗组合物
DE102021101216A1 (de) * 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CN113880810B (zh) * 2021-09-24 2023-02-28 厦门大学 一种核素标记的配合物及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015055318A1 (en) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Amide bond formation: beyond the myth of coupling reagents; E. Valeur, M. Bradley; Chem. Soc. Rev., 2009, 38, 606-631
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?; D. G. Brown, J. Boström; J. Med. Chem. 2016, 59, 4443-4458
JANSEN et al. ACS Med. Chem. Lett. 2013, 4, 491-496
JANSEN et al. J. Med. Chem. 2014, 57 (7), 3053-3074
LINDNER et al. J. Nucl. Med. 2018, 59 (9), 1415-1422
Nicholas A. Zia, Carleen Cullinane, Jessica K. Van Zuylekom, Kelly Waldeck, Lachlan E. McInnes, Gojko Buncic, Mohammad B. Haskali, Peter D. Roselt, Rodney J. Hicks,and Paul S. Donnelly: A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radio-labeled with Copper-64 with High Tumor Uptake and Retention; Angew. Chem. Int. Ed. 2019, 58, 14991 –14994;
Peptide Coupling Reagents, More than a Letter Soup; A. EI-Faham, F. Albericio; Chem. Rev. 2011, 111, 6557-6602
Zia, N.A. et al. Angw. Chem. Int. Ed. 2019, 58, 14991-14994

Also Published As

Publication number Publication date
CA3222226A1 (en) 2022-12-15
DE102021114711A1 (de) 2022-12-08
WO2022258637A1 (de) 2022-12-15
CN117642190A (zh) 2024-03-01
AU2022288744A9 (en) 2023-12-21
JP2024522200A (ja) 2024-06-11
AU2022288744A1 (en) 2023-12-14
KR20240019301A (ko) 2024-02-14
BR112023023149A2 (pt) 2024-01-23
EP4351663A1 (de) 2024-04-17
US20250235566A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
DE102021114711B4 (de) Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
EP4082581A1 (de) Markierungsvorläufer mit quadratsäure-kopplung
DE102019135564B4 (de) Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
EP3206720B1 (de) Konjugierte bisphosphonate für die diagnostik und therapie von knochenerkrankungen
DE69819478T2 (de) Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
DE102022105175A1 (de) Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik
WO2000018439A2 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
DE102021101216A1 (de) Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CN116217505B (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
DE69535094T2 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
DE19536783A1 (de) Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
WO2005087275A2 (en) Metal radiolabeled pet imaging agents
DE68919366T2 (de) Spaltbare linker zur reduzierung der akkumulierung von immunokonjugaten in nicht-zielorganen.
CN118119581A (zh) 放射性药物、其生产方法以及在疾病治疗、诊断和成像中的用途
DE60014375T2 (de) Uebergangsmetallkomplexe der vii-nebengruppe mit multidentaten aminopolycarboxylat-liganden und ein kit zu deren herstellung
DE102008045937A1 (de) Verbindung aus einem Metallion und einem Markierungsvorläufer und Verwendung der Verbindung
DE19860289C2 (de) Neue Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
EP4452326A1 (de) Fap-adressierendes pharmazeutikum für die therapie und diagnose von krebserkrankungen
EP4671258A1 (en) RADIOACTIVE MARKER OF RISEDRONIC ACID DERIVATIVE AND PRECURSOR COMPOUND THEREOF, CORRESPONDING PREPARATION PROCESS AND ASSOCIATED USE
DE60027873T2 (de) Moleküle für die behandlung und diagnose von tumoren
DE60032175T2 (de) Markierte ascorbinsäurederivate
JPH05505624A (ja) ラジオグラフィ造影剤として有用なヘキサデンテートリガンド類
EP0672673A1 (de) Nichtcyclische Chelatbildner auf Basis von Aminodialkylphosphoroxiden zur Herstellung von Technetium- oder Rheniumkomplexen
DE4311022C2 (de) Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
EP0588229A2 (de) Makrozyklische Chelatbildner zur Herstellung von Technetium- oder Rheniumkomplexen

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R081 Change of applicant/patentee

Owner name: MEDIANEZIA GMBH, DE

Free format text: FORMER OWNER: JOHANNES-GUTENBERG-UNIVERSITAET MAINZ, 55122 MAINZ, DE

R016 Response to examination communication
R081 Change of applicant/patentee

Owner name: MEDIANEZIA GMBH, DE

Free format text: FORMER OWNER: ATOMS FOR CURE GMBH, 10243 BERLIN, DE

R018 Grant decision by examination section/examining division
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: A61K0051080000

Ipc: A61K0051040000

R082 Change of representative

Representative=s name: ZOUNEK, ALEXIS, DIPL.-PHYS. DR. RER. NAT., DE

Representative=s name: DEHMEL & BETTENHAUSEN PATENTANWAELTE PARTMBB, DE

R020 Patent grant now final
R082 Change of representative

Representative=s name: DEHMEL & BETTENHAUSEN PATENTANWAELTE PARTMBB, DE

R082 Change of representative

Representative=s name: DEHMEL & BETTENHAUSEN PATENTANWAELTE PARTMBB, DE